Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 17/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35086 | 0.93 | NR1H2 (0.58) | NR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL35291 | 0.91 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL35310 | 0.89 | NR1H2 (0.55) | NR1H2NR1H3 | |
| SCHEMBL38526 | 0.89 | NR1H2 (0.59) | NR1H2NR1H3 | |
| SCHEMBL35004 | 0.87 | NR1H3 (0.52) | NR1H2NR1H3 | |
| SCHEMBL35536 | 0.84 | SMN1; SMN2 (0.49) | NR1H2NR1H3LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4015540 | 0.83 | NR1H2 (0.78) | NR1H2NR1H3 | |
| SCHEMBL35209 | 0.82 | MAPT (0.47) | NR1H2NR1H3LMNAMAPTSMN1; SMN2 | |
| SCHEMBL35112 | 0.81 | NR1H2 (0.65) | NR1H2NR1H3 | |
| SCHEMBL35356 | 0.81 | NR1H2 (0.51) | NR1H2NR1H3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | claimed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | claimed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | claimed |
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885LMNA 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.